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Abstract
In search of common risk alleles for prostate cancer that could contribute to high rates of the 
disease in men of African ancestry, we conducted a genome-wide association study (GWAS), with 
1,047,986 single nucleotide polymorphism (SNP) markers examined in 3,425 African American 
prostate cancer cases and 3,290 African American male controls. The most significant 17 novel 
associations in stage 1 were followed-up in 1,844 cases and 3,269 controls of African ancestry. 
We identified a novel risk variant on chromosome 17q21 (rs7210100; odds ratio per allele=1.51; 
p=3.4×10−13). The frequency of the risk allele is ~5% in men of African descent while it is rare in 
other populations (<1%). Further studies are needed to investigate the biological contribution of 
this allele to prostate cancer risk. These findings emphasize the importance of conducting GWAS 
in diverse populations.
Genome-wide association studies (GWAS) of prostate cancer have identified more than 30 
risk associated variants, which in aggregate are estimated to account for approximately 20% 
of the familial risk of prostate cancer1–12. Aside from admixture, and fine-mapping studies 
which identified multiple independent risk variants at 8q2413,14, and a more recent GWAS 
among Japanese men which identified five novel loci9, discoveries in prostate cancer have 
come from studies in men of European ancestry. However, prostate cancer incidence in men 
of African ancestry is greater than in non-African populations15, with the disparity 
presumably reflecting both differences in prevalence of environmental risk factors and 
susceptibility alleles that are shared among men of African descent. For example, the risk 
variants at 8q24, many of which are more common in men of African ancestry14, could 
contribute partly to the greater incidence of prostate cancer in this population, and provide 
some support for the hypothesis of a genetic contribution underlying racial/ethnic disparities 
in disease risk.
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We assembled a consortium of prostate cancer studies that included men of African ancestry 
and conducted a GWAS to search for additional risk loci that may be more common in men 
of African descent. Stage 1 included 3,621 African American prostate cancer cases and 
3,502 African American controls drawn from 11 studies (Supplementary Table 1, Online 
Methods). Genotyping in stage 1 was conducted using the Illumina Infinium 1M Duo. 
Following quality control exclusions (Online Methods), the stage 1 analysis consisted of 
1,047,986 SNPs (MAF≥0.01) examined in 3,425 cases and 3,290 controls.
In comparing, for all SNPs, the observed with the expected distribution of p-values from a 1-
df trend test there was evidence of inflation in the test statistic (λ=1.11). Principal 
components analysis highlights the high degree of admixture in this population and the over-
inflation diminished following additional adjustment for ancestry (λ=1.03; Supplementary 
Figure 1, Online Methods). The association of four SNPs achieved genome-wide 
significance in the stage 1 sample with p-values between 5.4×10−9 and 5.7×10−13 (Figure 1). 
These SNPs were located in known prostate cancer risk regions; three at 8q24 (rs10505483, 
rs1456315 and rs7824364 at 128.173–128.205 Mb (NCBI36) and one at 11q13 (rs7130881 
at 67.75 Mb).
We selected 17 SNPs (p<2×10−5) located outside of known prostate cancer risk regions to 
examine in a second stage. The associations of these 17 SNPs with prostate cancer risk were 
not influenced substantially by population stratification in the stage 1 sample, as evaluated 
by principal components analysis (Supplementary Table 2). The stage 2 sample included 
1,396 cases and 2,383 controls of African ancestry from seven independent studies: six U.S.-
based studies and one study in Ghana. Of the 17 SNPs, only marker rs7210100 at 17q21 was 
significantly associated with risk in the stage 2 studies (OR=1.55; p=2.5×10−5; Table 1). 
None of the other SNPs selected in stage 1 were significantly associated with risk in the 
stage 2 sample (all p-values >0.05); SNP rs13116912 was excluded due to deviating from 
Hardy-Weinberg Equilibrium in the majority of stage 2 studies. The results for all 17 SNPs 
in stage 1 and stage 2 are presented in Supplementary Table 3.
We further examined the association with rs7210100 in a third stage that included three 
studies among men of African descent, a study from the U.S (SCORE), a study in Senegal 
(PROGRÈS), and a study in Barbados (PCBP). SNP rs7210100 was found to be positively 
associated with risk in all three studies (stage 3: 471 cases and 904 controls; combined OR= 
2.07, p=1.5×10−5; Table 1).
Adjustment for global ancestry or local ancestry (African versus European) in the stage 1 
studies did not influence the results for rs7210100 (OR= 1.41 without adjustment for 
ancestry; OR=1.40 adjusted for global ancestry; OR=1.43 adjusted for global and local 
ancestry. The effect estimate for rs7210100 was also similar in men with <15% global 
European ancestry (1,251 cases and 1,325 controls; OR=1.41) as well as in cases and 
controls estimated to have 2 chromosomes of African ancestry at this location (2,214 cases 
and 2,080 controls; OR=1.47). We observed no evidence of heterogeneity of the association 
by study for this variant in the stage 1 (phet=0.89), stage 2 (phet=0.25), or stage 3 studies 
(phet=0.51), or among all studies (phet=0.58). Results for all SNPs examined in the 
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replication stages were also unaffected when adjusting for European ancestry in studies in 
which information on global ancestry was available (Supplementary Tables 4 and 5).
In combining the results across all three stages (5,262 cases and 6,554 controls), rs7210100 
was strongly and significantly associated with risk (OR = 1.51; 95% CI, 1.35–1.69; 
p=3.4×10−13). The risk for heterozygote and homozygote carriers was 1.49 (95 % CI, 1.32–
1.68) and 2.73 (95% CI, 1.50–4.96), respectively. We did not find any stronger signal with 
imputed SNPs to the Phase 2 HapMap populations in the surrounding region at chromosome 
17q21 (Figure 2, Supplementary Figure 2).
The association with rs7210100 was similar when stratifying on age (p=0.72) and first-
degree family history of prostate cancer (p=0.36). We also observed no significant 
difference in the association of rs7210100 with prostate cancer stage (p=0.94) or tumor 
grade (p=0.11) at diagnosis. However, the association with rs7210100 was greater for non-
advanced disease when classified based on stage and grade (Gleason Score <8 and localized 
stage, 2,433 cases and 6,554 controls: OR=1.67, p=8.6×10−12) than for advanced disease 
(Gleason Score ≥8 or non-localized disease, 1,719 cases and 6,554 controls: OR=1.27, 
P=5.0×10−3: phet = 6.0×10−3).
Among controls with PSA levels measured and ≤4 ng/ml (n=2,383) we found no significant 
association between PSA levels and rs7210100 genotype (p=0.58). Limiting the analysis to 
controls with PSA levels (<4 ng/ml) and cases from these studies did not change the 
association between rs7210100 and prostate cancer risk (n=3,157 cases and 2,383 controls; 
OR=1.62, p=4.5×10−8).
The variant rs7210100 is located in intron 1 of the ZNF652 gene on chromosome 17q21.32. 
ZNF652 encodes a zinc-finger protein transcription factor that has been shown to interact 
with the Eight-Twenty-One (ETO) protein, CBFA2T3, which acts as a transcriptional 
repressor by forming complexes with corepressor proteins and HDACs16. Co-expression of 
ZNF652 and the androgen receptor in prostate tumors has been associated with a decrease in 
relapse-free survival17. A common variant just upstream of the ZNF652 gene has also been 
associated with blood pressure in a GWAS of men and women of European ancestry18. 
Sequencing of the 5 coding exons of ZNF652 in 48 subjects (with over-sampling of risk 
allele carriers; Online Methods) did not reveal a coding variant strongly correlated with 
rs7210100. Further work is needed to map this locus in order to nominate optimal candidate 
markers, in addition to rs7210100, for functional studies in pursuit of regulatory effects of 
one or more variants in the region.
The risk allele of rs7210100 is relatively uncommon in men of African ancestry (4–7%), and 
is extremely rare (<1%) in non-African populations as reported by the 1000 Genomes 
Project. The frequency of the risk allele in men of West African ancestry (Ghana and 
Senegal) is very similar to that observed in African Americans as well as men from East 
Africa (Uganda, n=111; RAF=0.04). GWAS in populations of European ancestry have not 
pointed to this region of 17q21 as a risk locus for prostate cancer (Supplemental Figure 3). 
Together these observations suggest that the underlying biologically relevant allele may be 
limited to populations of African descent. As reported by the National Cancer Institute’s, 
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Surveillance, Epidemiology and End Results (SEER) Program, prostate cancer incidence in 
African American men is 1.56-times higher than the incidence of non-Hispanic Whites. 
Since approximately 10% of African American men carry this variant that increases their 
risk 1.50-fold over non-carriers, we estimate that this locus may be responsible for as much 
as 9% (95% CI, 6–12%) of the greater incidence of prostate cancer to African American 
men (Online Methods).
In summary, we detected a marker of risk for prostate cancer that appears specific to men of 
African descent, who have an increased incidence and mortality of this disease. These 
findings provide strong support for conducting GWAS in diverse populations to identify 
markers of risk that may be population-specific and which could contribute to racial and 
ethnic disparities in disease incidence. Further work is needed to characterize the 17q21 
region and conduct the functional studies required to understand the role of this germ-line 
variation in prostate cancer susceptibility.
Online Methods
Studies
The studies included in stage 1 were drawn from 11 epidemiological studies of prostate 
cancer among African American men. These studies included: The Multiethnic Cohort 
(MEC; 1,094 cases /1,096 controls), The Southern Community Cohort Study (SCCS, 
212/419), The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, 
286/269), The Cancer Prevention Study II Nutrition Cohort (CPS-II, 76/152), Prostate 
Cancer Case-Control Studies at MD Anderson (MDA, 543/474), Identifying Prostate Cancer 
Genes (IPCG, 368/172), The Los Angeles Study of Aggressive Prostate Cancer (LAAPC, 
296/303), Prostate Cancer Genetics Study (CaP Genes, 75/85), Case-Control Study of 
Prostate Cancer among African Americans in Washington, DC (DCPC, 292/359), King 
County (Washington) Prostate Cancer Study (KCPCS, 145/81), and The Gene-Environment 
Interaction in Prostate Cancer Study (GECAP, 234/92). These studies provided DNA 
samples for 3,621 cases and 3,502 controls.
Stage 2 included 1,396 cases and 2,383 controls from 7 studies: San Francisco Bay Area 
Prostate Cancer Study (SFPCS, 86/37), The Flint Men’s Health Study (FMHS, 135/353), 
The Multiethnic Cohort/Los Angeles County (MEC-LA, 554/557), North Carolina Prostate 
Cancer Study (NCPCS, 214/249), Wake Forest University Prostate Cancer Study (WFPCS, 
59/66), Washington University Prostate Cancer Study (WUPCS, 75/153), and The Ghana 
Men’s Health Study (GHS, 271/968). Stage 3 included 484 cases and 947 controls from 3 
studies: The Study of Clinical Outcomes, Risk and Ethnicity (SCORE, 152/280), Prostate-
Genetique-Recherche-Senegal (PROGRÈS, 86/414) and Prostate Cancer in a Black 
Population (PCBP, 246/253). Detailed information about the design and organization of 
each study is provided in the Supplementary Note.
Genotyping and Quality Control
Genotyping in stage 1 (3,621 cases and 3,502 controls) was conducted using the Illumina 
Infinium Human1M-Duo. Samples (n=408) were removed based on the following exclusion 
criteria: 1) unknown replicates across studies, 2) call rates <95%; 3) >10% mean 
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heterozygosity on the X chromosome and/or <10% mean intensity on the Y chromosome, 4) 
ancestry outliers, and; 5) samples that were related (discussed below). The concordance rate 
for 158 replicate samples was 99.99%. Starting with 1,153,397 SNPs, we removed SNPs 
with <95% call rate, MAFs <1%, or >1 QC mismatch based on sample replicates 
(n=105,411). The analysis included 1,047,986 SNPs among 3,425 cases and 3,290 controls. 
We used PLINK to calculate the probabilities of sharing 0, 1, and 2 alleles (Z = Z0, Z1, Z2) 
across all possible pairs of samples to determine individuals who were likely to be related to 
others within and across studies. We identified 167 pairs of related subjects (MZ twin, 
parent-offspring, full and half-sibling pairs), based on the values of their observed 
probability vector Z being within 1 SD of the expected values of Z for their respective 
relationship. The criterion for removal was such that individuals that were connected with a 
higher number of pairs were chosen for removal. In all other cases, one of the two members 
was randomly selected for removal. A total of 141 subjects were removed.
The EIGENSTRAT software was used to calculate eigenvectors that explained genetic 
differences in ancestry among samples in the study19. We included data from both HapMap 
populations (CEPH (Utah residents with ancestry from northern and western Europe) 
(CEU), Japanese in Tokyo, Japan (JPT), Yoruba in Ibadan, Nigeria (YRI), and African 
ancestry in Southwestern U.S. (ASW)) and our study, so that comparisons to reference 
populations of known ethnicity could be made. A total of 2,546 ancestry-informative SNPs 
from the Illumina array were selected based on low inter-marker correlation and ability to 
differentiate between samples of African and European descent. An individual was subject 
to filtering from the analysis if his value along eigenvector 1 or 2 was outside of 4 SDs of 
the mean of each respective eigenvector. We identified 108 individuals who met this 
criterion. Eigenvector 1 was highly correlated (ρ=0.997, p<1 × 10−16) with percentage of 
European ancestry, estimated in HAPMIX20. Together the top 10 eigenvectors explain 21% 
of the global genetic variability among subjects.
Genotyping in the stage 2 and 3 studies was conducted using the TaqMan allelic 
discrimination assay. In stage 2, we removed samples missing data for >3 SNPs (n=36). To 
assess genotyping reproducibility each study included replicate samples; the concordance 
was >98% for each SNP within each study. SNP rs13116912 deviated from HWE in all but 
one of the stage 2 studies and was removed from the stage 2 analysis. No other SNP 
deviated from HWE (i.e. P<0.01 in >2 studies) in stage 1 or 2. The call rate for rs7210100 
was very high in stage 1 (99.9%) and similar in cases (99.9%) and controls (99.9%). The 
call rate for this SNP was also very high in stages 2 (99.8% overall, 99.9% in cases and 
99.8% in controls) and 3 (96.1% overall, 97.3% in cases and 95.5% in controls).
Sequencing
Bi-directional sequencing of rs7210100 and the 5 coding exons of ZNF652 was performed 
in 48 subjects (20 homozygous for the risk variant, 20 heterozygous for the risk variant and 
8 homozygous for the wild-type allele.) Primers were designed at least 50 bases upstream 
and downstream from each exon.
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Statistical Analysis
In stage 1, we tested the association of each SNP and prostate cancer risk using a 1-d.f. χ2 
likelihood ratio test from a logistic regression analysis adjusted for age, study and the first 
10 eigenvectors estimated by principal components analysis19. Over-inflation of the test 
statistic was examined with and without adjustment for ancestry and visualized with 
quantile-quantile plots. Lambdas were estimated as the median of the test statistics divided 
by 0.456 (the median of the 1-d.f. χ2 null distribution). Age-adjusted odds ratios (OR) and 
95% confidence intervals (95% CI) for each SNP were estimated from the same logistic 
regression model. At each locus and for each participant, local ancestry was defined as the 
estimated number of European chromosomes (continuous between 0–2) carried by the 
participant, estimated via the HAPMIX program20. Local ancestry at the 17q21 locus was 
evaluated as a confounder in the analysis of rs7210100.
Phased haplotype data from the founders of the CEU and YRI HapMap Phase 2 samples 
were used to infer LD patterns in order to impute untyped markers. We carried out genome-
wide imputation using the software MACH21. The Rsq metric was used as a threshold in 
determining which SNPs to filter from analysis (Rsq<0.3). Imputed SNPs in the 17q21 risk 
region, as shown in Figure 2, were examined in association with prostate cancer risk as 
described for typed SNPs above.
In stage 2, the SNPs were analyzed using logistic regression controlling for age and study 
(in the pooled analysis). Information regarding European ancestry was available for 7 
studies included in stages 2 and 3. As observed in stage 1 (Supplementary Table 2) the OR 
for rs7210100 was similar with and without adjustment for estimated European ancestry in 
these studies (Supplementary Table 4). The results for rs7210100 in stage 2, stage 3 and 
stages 1+2+3 are presented without adjustment for ancestry.
Association testing in the stage 2 and stage 3 studies was performed using logistic 
regression, adjusting for age and study. For seven of the replication studies, information 
about global European ancestry was available and examined as a confounding factor for 
variant rs7210100. For rs7210100, a combined analysis of all stages was performed adjusted 
for age and study. Heterogeneity of the OR across studies was evaluated using a likelihood 
ratio test.
Effect modification by age and first-degree family history of prostate cancer was assessed in 
stratified analyses, and significance determined comparing the model with and without the 
cross-product term using a likelihood ratio test. We also examined the association of 
rs7210100 genotype with stage, Gleason Score as well as the combination of stage and 
grade, with advanced disease defined as Gleason Score≥8 or stage ≥2 (non-localized 
disease) and non-advanced disease defined as Gleason Score<8 and stage=1 (localized 
disease). Case-only analysis was used to test for differences in the association of rs7210100 
with disease phenotypes. The association of rs7210100 with least-squares geometric mean 
PSA levels was examined using multiple linear regression adjusting for age, body mass 
index and study.
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We estimated the risk ratio between populations of different ancestral origin (African / 
European) due to rs7210100 as RR= [(1-pA)2+2pA(1-pA)RR1+pA2RR2]/(1-pE)2+2pE(1-
pE)RR1+pE2RR2]. Here pA is the risk allele frequency in African origin populations, pE is 
the risk allele frequency in European populations and RR1 is the relative risk associated with 
carrying 1 copy of the risk allele (compared to none) and RR2 is the relative risk associated 
with carrying 2 copies of the risk allele. We used values pA = 0.05, pE = 0, RR1 = 1.5, and 
RR2 = 1.52 so that the risk ratio between populations due to the influence of this risk allele 
was estimated to be equal to 1.050625. Using the SEER incidence rates of prostate cancer in 
African Americans (234.6 per 100,000) and non-Hispanic Whites (150.4 cases per 100,000), 
we estimated the ratio of risks between these populations as 234.6/150.4 = 1.56. The 
percentage of greater risk to African Americans that may be associated with rs7210100 was 
estimated as 1-[(1.56–1.050625)/(1.56-1)] × 100.
URLs
SEER: http://seer.cancer.gov/
LocusZoom: http://csg.sph.umich.edu/locuszoom/
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A plot of the −log10 P-values by chromosome.
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Figure 2. 
A regional plot of the −log10 P-values for genotyped (squares) and imputed (circles) SNPs at 
the chromosome 17q21 risk locus in the stage 1 African American sample. The shading 
depicts the strength of the correlation (r2) between SNP rs7210100 and the SNPs tested in 
the region. The correlation is estimated in the YRI population from the 1000 Genomes 
Project (June 2010). Also shown are human genome build 18 coordinates (Mb), 
recombination rates in centimorgans (cM) per megabase (Mb) and genes in the region. The 
plot was generate using LocusZoom.
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Table 1
The association of variant rs7210100 at 17q21 with prostate cancer risk in men of African ancestry.
Stage 1 Studies Cases/Controlsa RAF in controls OR(95% CI)b P-valuec
MEC 1060/1055 0.04 1.58(1.21–2.08) 8.8×10−4
SCCS 201/412 0.05 1.40(0.85–2.31) 0.19
PLCO 227/239 0.05 1.44(0.82–2.52) 0.21
CPS-II 64/112 0.07 0.66(0.24–1.78) 0.41
MDA 527/437 0.05 1.39(0.95–2.02) 0.089
IPCG 354/157 0.05 1.54(0.84–2.82) 0.17
LAAPC 288/287 0.06 0.94(0.57–1.56) 0.81
CaP Genes 71/85 0.06 1.72(0.78–3.82) 0.18
DCPD 263/341 0.07 1.14(0.75–1.75) 0.54
KCPCS 141/75 0.05 0.95(0.42–2.16) 0.90
GECAP 224/89 0.05 2.47(1.14–5.34) 0.022
Combined 3,420/3,289 1.40(1.21–1.62) 5.2×10−6
PHet=0.89d
Stage 2 Studies
SFPCS 86/36 0.04 1.86(0.53–6.55) 0.34
FMHS 125/339 0.06 1.70(0.98–2.93) 0.058
MEC-LAC 551/555 0.04 1.92(1.30–2.83) 9.7×10−4
NCPCS 214/249 0.06 0.92(0.51–1.66) 0.79
WFPCS 58/65 0.04 1.90(0.56–6.42) 0.30
WUPCS 73/153 0.04 1.96(0.76–5.03) 0.16
GHS 264/964 0.07 1.37(0.94–2.01) 0.11
Combined 1,371/2,361 1.55(1.26–1.89) 2.5×10−5
PHet=0.25d
Stage 3 Studies
SCORE 146/267 0.05 1.58(0.88–2.83) 0.13
PROGRÈS 79/395 0.05 2.64(1.36–5.10) 4.0×10−3
PCBP 246/242 0.05 2.02(1.20–3.39) 7.9×10−3
Combined 471/904 2.07(1.49–2.88) 1.5×10−5
PHet=0.51d
Stages 1+2+3 5,262/6,554 1.51(1.35–1.69) 3.4×10−13
PHet=0.58d
aNumber of cases and controls with genotype data for rs7210100.
bAdjusted for age and eigenvectors 1–10 in stage 1 (and study in pooled analysis). Adjusted for age in stage 2 and stage 3. Adjusted for age and 
study in stage 1+2+3 analysis.
c
P for trend (1-d.f.).
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d
Test of heterogeneity. RAF: risk allele frequency.
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